C4 Therapeutics, Inc. (CCCC) vs Avita Medical Inc. (RCEL)
A side-by-side comparison of C4 Therapeutics, Inc. and Avita Medical Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CCCC
C4 Therapeutics, Inc.
$2.88HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
RCEL
Avita Medical Inc.
$12.99HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT
Total return — CCCC vs RCEL
growth of $100 · dividends reinvested · last 6yCCCC -88.3% (-30.0%/yr)RCEL -47.9% (-10.3%/yr)RCEL compounded faster over this window
CCCC RCEL
CCCC vs RCEL: by the numbers
- •RCEL is the larger company ($323M vs $318M market cap).
- •Both run net losses; RCEL's is the smaller (-56.96% vs -289.44% net margin).
- •RCEL grew revenue faster over the past five years (20.94% vs 0.65% CAGR).
Metrics side by side
Valuation
| Metric | CCCC | RCEL |
|---|---|---|
| P/S ratio | 9.09 | 4.27 |
| P/B ratio | 1.29 | N/A |
Profitability
| Metric | CCCC | RCEL |
|---|---|---|
| Gross margin | 77.81% | 81.56% |
| Operating margin | -290.68% | -59.40% |
| Net margin | -289.44% | -56.96% |
| ROE | -41.02% | N/A |
| ROIC | -35.92% | -136.92% |
Growth (annualized)
| Metric | CCCC | RCEL |
|---|---|---|
| Revenue CAGR (5Y) | 0.65% | 20.94% |
| Total return CAGR (5Y) | -41.77% | -5.28% |
Frequently asked
- Which has grown faster, CCCC or RCEL?
- Over the past five years, RCEL grew revenue faster — CCCC at a 0.65% CAGR versus RCEL at 20.94%.
- How have CCCC and RCEL total returns compared?
- Over the past 5 years, CCCC delivered -41.77% and RCEL delivered -5.28% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
C4 Therapeutics ROEAvita Medical ROEC4 Therapeutics operating marginAvita Medical operating marginC4 Therapeutics revenue growthAvita Medical revenue growthC4 Therapeutics free cash flowAvita Medical free cash flow
C4 Therapeutics & Avita Medical appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.